Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Lilly, which makes weight loss injections, unveils trial result showing Type 2 diabetes sufferers lost 8% of body weight ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker ...

It's little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several ...

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of ...